These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 26837339)

  • 21. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
    Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
    Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
    [No Abstract]   [Full Text] [Related]  

  • 22. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
    Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
    Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
    Escorcia FE; Steckler JM; Abdel-Atti D; Price EW; Carlin SD; Scholz WW; Lewis JS; Houghton JL
    Mol Imaging Biol; 2018 Oct; 20(5):808-815. PubMed ID: 29508263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Evaluation of Antibody Modification and
    Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW
    Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
    Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
    Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging.
    Sharma SK; Wuest M; Wang M; Glubrecht D; Andrais B; Lapi SE; Wuest F
    EJNMMI Res; 2014 Dec; 4(1):60. PubMed ID: 26116121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
    Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
    J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of
    Stergiou N; Wuensche TE; Schreurs M; Mes I; Verlaan M; Kooijman EJM; Windhorst AD; Helboe L; Vergo S; Christensen S; Asuni AA; Jensen A; Van Dongen GAMS; Bang-Andersen B; Vugts DJ; Beaino W
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1306-1317. PubMed ID: 36635462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
    England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
    Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer.
    Fung K; Sharma SK; Keinänen O; Roche KL; Lewis JS; Zeglis BM
    Mol Pharm; 2020 Aug; 17(8):3140-3147. PubMed ID: 32644804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
    Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
    Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Pandya DN; Bhatt NB; Almaguel F; Rideout-Danner S; Gage HD; Solingapuram Sai KK; Wadas TJ
    J Nucl Med; 2019 May; 60(5):696-701. PubMed ID: 30442753
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis and pre-clinical evaluation of an (18)F-labeled single-chain antibody fragment for PET imaging of epithelial ovarian cancer.
    Sharma SK; Wuest M; Way JD; Bouvet VR; Wang M; Wuest FR
    Am J Nucl Med Mol Imaging; 2016; 6(3):185-98. PubMed ID: 27508105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Sharma SK; Mack KN; Piersigilli A; Pourat J; Edwards KJ; Keinänen O; Jiao MS; Zhao H; White B; Brooks CL; de Stanchina E; Madiyalakan MR; Hollingsworth MA; Radhakrishnan P; Lewis JS; Zeglis BM
    Clin Cancer Res; 2022 Mar; 28(5):948-959. PubMed ID: 34907079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
    Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.